Mimedx Group Inc is a biotech company focused on the development and commercialization of regenerative medicine products, particularly those that utilize allogeneic placental tissues. The company aims to provide advanced solutions for wound care, surgical applications, and orthopedic treatments through its innovative therapies that promote healing and tissue regeneration. Mimedx's products are designed to support patient recovery by harnessing the natural properties of human placental tissues, thereby enhancing the body’s own healing processes. By combining scientific expertise with cutting-edge technology, Mimedx is committed to improving patient outcomes in various medical fields. Read More
MIMEDX Group (MDXG) reports record Q2 2025 earnings, beating revenue and EPS estimates with $98.61M in sales and $0.10 EPS. Stock surges 11.8% post-announcement.
AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.
Cantor Fitzgerald has initiated coverage on MIMEDX, highlighting its strong market presence in wound care and surgical recovery. Targeting a $3.9 billion market, MIMEDX products demonstrate a 97% wound closure rate for diabetic foot ulcers, cost-effectiveness, and significant growth potential.
